Chronic caloric restriction (CR) has powerful anticarcinogenic actions in both preclinical
and clinical studies but may be difficult to sustain. As an alternative to CR, there has been …

Oestrogen receptor-positive (ER + ) breast cancer is a major cause of cancer death in
women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …

Defects in p53 function, which occur frequently in human cancers due to mutations in TP53
or disruptions in the p53 regulatory pathway, render cells dependent on CHK1 (Checkpoint …

Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are
required for the initiation and progression of various malignancies 1 , 2 . Pharmacological …

Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2
somatic mutations in cancers lacking HER2 gene amplification. To determine the phenotype of …

… Ma, Minetta C. Liu, Anna Maria Storniolo, Mothaffar F. Rimawi, Andres Forero-Torres,
Antonio C. … Ma, Minetta C. Liu, Anna Maria Storniolo, Antonio C. Wolff, Madlyn Ferraro …

To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome
comparisons with originating breast cancers representative of the major intrinsic …

Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive
(ER + ) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through
enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability …

Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER)–positive
primary breast cancer triaged to chemotherapy when the protein encoded by the …